Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

36.53USD
2 Dec 2016
Change (% chg)

$-0.04 (-0.11%)
Prev Close
$36.57
Open
$36.70
Day's High
$37.10
Day's Low
$36.43
Volume
1,208,424
Avg. Vol
1,693,111
52-wk High
$66.55
52-wk Low
$36.43

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.68
Market Cap(Mil.): $39,344.21
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 3.51

Financials

  TEVA.N Industry Sector
P/E (TTM): 22.41 29.13 29.87
EPS (TTM): 1.73 -- --
ROI: 3.34 15.56 14.95
ROE: 5.87 16.69 16.29

Teva Pharm to market medical cannabis inhaler in Israel

JERUSALEM Israel's Teva Pharmaceuticals has partnered with Tel Aviv-based Syqe Medical to market in Israel medical cannabis for pain management that is administered with an inhaler.

28 Nov 2016

Teva Pharm to market medical cannabis inhaler in Israel

JERUSALEM, Nov 28 Israel's Teva Pharmaceuticals has partnered with Tel Aviv-based Syqe Medical to market in Israel medical cannabis for pain management that is administered with an inhaler.

28 Nov 2016

BRIEF-Aurobindo Pharma unit Arrow Generiques to buy select assets in France from Teva

* Aurobindo Pharma Ltd says Arrow Generiques to acquire select assets in France from Teva

25 Nov 2016

UPDATE 1-Teva trims 2016 outlook on drug launch delays

* Cuts 2016 revenue outlook to $21.6-$21.9 bln from $22-$22.5 bln

15 Nov 2016

BRIEF-Teva Pharm on 2016 outlook

* Says cut 2016 outlook due to lower revenue from new drug launches which will now come in 2017 or 2018

15 Nov 2016

Teva Pharm Q3 beats estimates as acquisition lifts revenue

TEL AVIV, Nov 15 Teva Pharmaceutical Industries reported better than expected third-quarter profit as sales were boosted by its $40.5 billion acquisition of Allergan's generic drug business on Aug. 2.

15 Nov 2016

BRIEF-Teva Pharmaceutical Industries Q3 gaap EPS $0.35

* Teva Pharmaceutical Industries Ltd - generic medicines revenues in q3 of 2016 were $2.9 billion, an increase of 32 pct compared to q3 of 2015

15 Nov 2016

BRIEF-Teva Pharmaceutical appoints David Stark as chief legal officer

* Announced appointment of David Stark to position of chief legal officer

08 Nov 2016

BRIEF-Teva announces approval of generic Tribenzor in the U.S.

* Teva Pharmaceutical Industries - approval of generic Tribenzor in U.S. and is in final stages of launch preparation

07 Nov 2016

BRIEF-Teva Pharmaceuticals and IBM expand global partnership

* Teva Pharmaceuticals and IBM expand global partnership to enable drug development and chronic disease management with Watson Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

26 Oct 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF68.75 -0.10
Biogen Inc (BIIB.OQ) $297.19 +1.41

Earnings vs. Estimates